Company: TAK
Filing Date: 2025-05-08
Form Type: 6-K
Source: 0001395064-25-000048
Chunk: 14

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-05-08
Form: 6-K
Chunk 14
---
                  |     | 4,579.8 |     |          |     | 316.1 |     |          |     |  7.4 | % |     |     |  2.8 | %                         |
| Core operating profit                                              |     |                           |     |      | 1,054.9 |     |                  |     | 1,162.6 |     |          |     | 107.8 |     |          |     | 10.2 | % |     |     |  4.9 | %                         |
| Core net profit for the year                                       |     |                           |     |      |   756.9 |     |                  |     |   775.8 |     |          |     |  18.9 |     |          |     |  2.5 | % |     |     | -3.4 | %                         |
| Core net profit for the year attributable to owners of the Company |     |                           |     |      |   756.8 |     |                  |     |   775.6 |     |          |     |  18.8 |     |          |     |  2.5 | % |     |     | -3.4 | %                         |
| Core EPS (yen)                                                     |     |                           |     |      |     484 |     |                  |     |     491 |     |          |     |     7 |     |          |     |  1.5 | % |     |     | -4.3 | %                         |

#### Core Revenue
Core Revenue for the fiscal year ended March 31, 2025 was JPY 4,579.8 billion (JPY +316.1 billion and +7.4% AER, +2.8% CER). The increase is primarily attributable to favorable foreign exchange rates and growth from business momentum primarily led by Takeda’s Growth and Launch Products* which totaled JPY 2,201.9 billion (JPY +375.9 billion and +20.6% AER, +14.7% CER), partially offset by lower sales of VYVANSE in the U.S. and AZILVA in Japan, which were impacted by generic competition following loss of exclusivities.

* Takeda’s Growth and Launch Products for the fiscal year ended March 31, 2025

GI: